Compare Biogen Inc (BIIB) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Open Text Corporation — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Open Text Corporation trades at $23.97 (market cap $5.80B). The key difference: Biogen Inc is far larger — about 5.2× Open Text Corporation's market cap, and Open Text Corporation pays a 4.67% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | OTEX | |
|---|---|---|
Market Cap | $30.13B | $5.80B |
Sector | Health | Technology |
52-Week High | $216.63 | $39.69 |
52-Week Low | $128.93 | $20.01 |
Enterprise Value | $37.20B | $10.81B |
Dividend Yield | — | 4.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Open Text Corporation (OTEX) trades at $23.95, down 3.11% over the past day. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company shows strong profitability with a 73.74% gross margin and has beaten earnings estimates for the last three quarters. Recent news highlights Q4 2026 results with cloud revenue growth and strategic investments in AI.
The investment outlook is positive given attractive valuations like a P/E of 9.29 and a consensus price target of $29.33 implying significant upside. Key risks include execution of growth initiatives and competitive pressures in the software sector. Analyst sentiment is mixed but leans cautious with a majority hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
